Dr. Lin Zhao 赵林
Chief Physician, Associate Professor
Department of Medical Oncology, Peking Union Medical College Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and comprehensive cancer treatment, with a special focus on gastrointestinal tumors.
Dr. Zhao earned an MD from Peking Union Medical College in 1998 and has worked at Peking Union Medical College Hospital since. Promoted to Associate Chief Physician in 2008, Dr. Zhao completed fellowships at Columbia University and UCLA. Research focuses on comprehensive cancer care and gastrointestinal tumors. Two abstracts were accepted by ASCO GI and the ASCO Annual Meeting.
Professional roles
- Member, Chinese Society of Clinical Oncology (CSCO)
- Member, Chemotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Lin). Papers usually list the name as Lin Zhao or Zhao L.
Selected publications
85 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Surg Oncol, 2026 (senior author): ASO Author Reflections: Can Graded Histologic Regression Guide Postoperative Chemotherapy Regimen Switching for Locally Advanced Gastric Cancer?. PubMed 42734704
- Gastric Cancer, 2026 (senior author): Baseline IL-6 independently predicts severe immune-related toxicity and poor survival in advanced gastric cancer treated with immunotherapy. PubMed 42572075
- Ther Adv Med Oncol, 2026 (senior author): High-titer antinuclear antibodies are associated with severe immune-related toxicity and exploratory survival outcomes in advanced gastric cancer immunotherapy. PubMed 42571170
- Discov Oncol, 2025 (senior author): Causal relationships between immune-related adverse events, immune cell characteristics, and plasma metabolites: insights from Mendelian randomization study. PubMed 40591041
- Oncol Lett, 2025 (senior author): Malignant mesothelioma with a novel BAP1 germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report. PubMed 40463358
- Ann Med, 2023 (first author): Factors contributing to development and resolution of dysglycemia in patients with pheochromocytomas and catecholamine-secreting paragangliomas. PubMed 37129505
- Clin Exp Med, 2023 (senior author): Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. PubMed 37016065
- Endocrine, 2023 (first author): The clinical characteristics of patients with normotension in pheochromocytomas and paragangliomas. PubMed 36749542
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion